Mental Health PTSD
EpiVario Raises $445K in Seed Funding to Develop a Novel Drug to Treat Post-Traumatic Stress Disorder (PTSD)
Company is developing novel drug to treat memory-related psychiatric disorders by targeting a non-essential gene – acetyl CoA synthetase (ACSS2)
